Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD takes issue with University Medical

This article was originally published in The Tan Sheet

Executive Summary

The National Advertising Division recommends University Medical Pharmaceuticals discontinue claims that compare the effects of its WrinkleFree Eyes to those of Botox, the Council of Better Business Bureaus division says Aug. 19. NAD says the firm should discontinue claims such as, "Clinically proven to reduce wrinkle appearance up to 85 percent in only 20 minutes" and "Truly effective topical alternative to Botox" because of a lack of evidence. NAD asks that the firm remove before-and-after photographs because the lighting, posing and cosmetic application are different in the first photo. The firm said the photos are not misleading. The Irvine, Calif., firm said it is disappointed with NAD's decision, but will consider the recommendations and modify its advertising accordingly

You may also be interested in...



AcneFree Is Latest In Rash Of NAD Decisions Against University Medical

University Medical Pharmaceuticals continues to have trouble supporting its competitive marketing claims to the satisfaction of the National Advertising Division

Global Catastrophe Or Passing Nuisance? Pharma’s Coronavirus Views

While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.

Topics

UsernamePublicRestriction

Register

PS103300

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel